Table of Contents

company-logo

Ascentage Pharma Group International, a clinical-stage biotechnology company, engages in developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in the United States and Mainland China. Its primary product HQP1351, a BCR-ABL inhibitor targeting BCR-ABL mutants, including those with the T315I mutation, as well as for patients with tyrosine kinase inhibitor resistant chronic phase chronic myeloid leukemia. It also has APG-2575, an orally administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors, which is under Phase Ib/II clinical study; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interaction for treating solid tumors and hematological malignancies; and APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection. In addition, it is involved in the development of APG-1252, a small molecule drug to restore apoptosis through selective inhibition of the Bcl-2 and Bcl-xL proteins for SCLC, lymphoma, and other solid tumors; APG-2449 for non-small-cell lung carcinoma; APG-5918, an orally available and selective EED inhibitor with a best-in-class potential that is under pre-clinical stage; APG-265, which is in the IND-enabling stage for hematological malignancies and solid tumors; and UBX1967/1325 targeting Bcl family indicated for DME that is under Phase II development. Ascentage Pharma Group International has collaboration relationships with major biotechnology and pharmaceutical companies, and academic institutions, which include Innovent Biologics, Inc.; National Cancer Institute; Pfizer Inc.; and Clover Biopharmaceuticals (Hong Kong) Co., Limited. The company was founded in 2009 and is headquartered in Suzhou, China.

Ascentage Pharma International Dividend Announcement

• Ascentage Pharma International does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Ascentage Pharma International dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Ascentage Pharma International Dividend History

Ascentage Pharma International Dividend Yield

Ascentage Pharma International current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Ascentage Pharma International stock? Use our calculator to estimate your expected dividend yield:

Ascentage Pharma International Financial Ratios

P/E ratio-34.81
PEG ratio0.37
P/B ratio16.37
ROE-87.15%
Payout ratio0.00%
Current ratio1.84
Quick ratio1.83
Cash Ratio1.03

Ascentage Pharma International Dividend FAQ

Does Ascentage Pharma International stock pay dividends?
Ascentage Pharma International does not currently pay dividends to its shareholders.
Has Ascentage Pharma International ever paid a dividend?
No, Ascentage Pharma International has no a history of paying dividends to its shareholders. Ascentage Pharma International is not known for its dividend payments.
Why doesn't Ascentage Pharma International pay dividends?
There are several potential reasons why Ascentage Pharma International would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Ascentage Pharma International ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Ascentage Pharma International has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Ascentage Pharma International a dividend aristocrat?
Ascentage Pharma International is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Ascentage Pharma International a dividend king?
Ascentage Pharma International is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Ascentage Pharma International a dividend stock?
No, Ascentage Pharma International is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Ascentage Pharma International stocks?
To buy Ascentage Pharma International you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Ascentage Pharma International stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.